Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $187 | $240 | $231 | $236 |
| % Growth | -22.1% | 4.1% | -2.1% | – |
| Cost of Goods Sold | $49 | $54 | $49 | $48 |
| Gross Profit | $138 | $186 | $182 | $188 |
| % Margin | 73.7% | 77.5% | 78.8% | 79.7% |
| R&D Expenses | $121 | $160 | $181 | $230 |
| G&A Expenses | $55 | $69 | $77 | $76 |
| SG&A Expenses | $154 | $184 | $207 | $209 |
| Sales & Mktg Exp. | $100 | $114 | $131 | $143 |
| Other Operating Expenses | $0 | -$18 | $0 | $0 |
| Operating Expenses | $275 | $327 | $388 | $440 |
| Operating Income | -$137 | -$141 | -$206 | -$252 |
| % Margin | -73.3% | -58.6% | -89.2% | -106.7% |
| Other Income/Exp. Net | -$1 | -$396 | -$8 | -$113 |
| Pre-Tax Income | -$139 | -$537 | -$214 | -$365 |
| Tax Expense | $4 | -$28 | -$5 | -$2 |
| Net Income | -$135 | -$508 | -$206 | -$354 |
| % Margin | -72% | -211.5% | -89.5% | -150% |
| EPS | -0.31 | -1.16 | -0.47 | -0.81 |
| % Growth | 73.3% | -146.8% | 42% | – |
| EPS Diluted | -0.31 | -1.16 | -0.47 | -0.81 |
| Weighted Avg Shares Out | 438 | 438 | 438 | 438 |
| Weighted Avg Shares Out Dil | 438 | 438 | 438 | 438 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10 | $0 | $3 |
| Interest Expense | $7 | $17 | $0 | $0 |
| Depreciation & Amortization | $15 | $68 | $43 | $41 |
| EBITDA | -$122 | -$450 | -$163 | -$209 |
| % Margin | -65.3% | -187.5% | -70.5% | -88.5% |